Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:51:05.221Z.
Calculation as of: 2026-10-06T14:51:05.221Z.
Quote observation: 2026-10-06T14:50:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5ea7848df566bb1fba137e14a23bd7a424b67da13a14cf2752e181034030ce3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$32.98M
PS Ratio
1.05
TTM Avg
22.78
3Y Avg
25.26
5Y Avg
324.62
Market Cap
$32.78M
PS Ratio
2.79
TTM Avg
7.06
3Y Avg
18.39
5Y Avg
15.88
Market Cap
$31.36M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartBeam, Inc. (BEAT) | $33.20M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $32.98M | 1.05 | 22.78 | 25.26 | 324.62 |
| EUDA Health Holdings Limited (EUDA)vs › | $32.78M | 2.79 | 7.06 | 18.39 | 15.88 |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.93M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.48M | 2.84 | 2.34 | 2.93 | 2.48 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.80M | N/A | N/A | N/A | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.47M | 0.25 | 0.27 | 0.24 | 0.25 |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $31.26M | N/A | 74.19 | 53.76 | 254.70 |
| MDxHealth S.A. (MDXH)vs › | $31.11M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
